Retension (RTSN) traded down -6.62 % during a 24 hours period ending at 06:54 PM Central Europe on Tuesday 27th. One Retension stock can currently be bought for about USD 14.05 on popular exchanges. Retension has a current market capitalization of USD 118.2 mn and approximately USD 672.1 k worth of Retension was traded on exchanges in the last 24 hours. Simple moving average of last 200 days is at USD 13.66. The highest price of past 52 weeks was recorded at USD 18.64 on 10/19/2026. 52 weeks low was at USD 9.66 on 10/09/2026.
Here is how related stocks have performed in the past 24 hours:
Ncs Multistage (NCSM) traded up 3.31 % and now trades at USD 53.35. Ncs Multistage has a market capitalisation of USD 140 mn. Ncs Multistage has a current price to earnings ratio of 12.56.
Eagle Nuclear Energy (NUCL) traded down -0.63 % and now trades at USD 4.74. Eagle Nuclear Energy has a market capitalisation of USD 141.4 mn. Eagle Nuclear Energy Corp. (NASDAQ: NUCL) continues to advance its Aurora Uranium Project toward a Pre‑Feasibility Study, with all major contractors in place and a 27,000‑foot drill program ready to commence pending regulatory approvals in Oregon. The company has engaged new technical and government affairs advisors to support the drilling and resource upgrade efforts. Eagle’s cash position remains robust, with no debt, and the company has been added to a global uranium index, potentially enhancing its exposure to institutional investors. Aurora, which holds a significant equity interest in Eagle, notes that its share price trades at a discount to the underlying value of the holding, reflecting market perceptions of the project’s development stage. Overall, Eagle’s focus remains on progressing the Aurora project toward a second‑half 2027 feasibility milestone while maintaining a stable financial base.
Lee (LEE) traded down -2.37 % and now trades at USD 6.22. Lee has a market capitalisation of USD 139.6 mn.
Atrium Therapeutics (RNA) traded down -1.83 % and now trades at USD 8.24. Current market capitalisation for Atrium Therapeutics is USD 140.3 mn. Atrium Therapeutics announced that the first patient has entered its Phase 1/2 Corventis trial for PRKAG2 syndrome, marking a significant step toward a potential disease‑modifying therapy for this rare cardiomyopathy. The study, enrolling approximately 37 participants, will assess safety, tolerability, and preliminary efficacy of ATR 1072, an RNA‑based treatment designed to silence mutant PRKAG2 messenger RNA. The company expects to release early proof‑of‑concept data in the second half of 2027. This development follows Atrium’s broader pipeline, which includes candidates for other genetic heart conditions, and underscores the firm’s focus on precision RNA therapeutics targeting the heart.
Bhav Acquisition (BHAV) traded flat 0 % and now trades at USD 10.1. Bhav Acquisition has a market capitalisation of USD 141.7 mn.